Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, WebMD expand partnership

This article was originally published in The Tan Sheet

Executive Summary

FDA and WebMD Health Corp. expand their partnership to provide consumers with increased access to FDA's consumer information, the agency says Oct. 29. The second phase of the partnership launched in December 2008 includes additional multimedia tools and content on WebMD's Web site about allergies and asthma, children's health, diabetes, heart health and vitamins and supplements, FDA says. A release says the partnership increased FDA's consumer reach when the agency warned the public to stop using Iovate Pharmaceuticals' weight-loss product Hydroxycut because of serious adverse event reports (1"Health News Daily" May 4, 2009)

You may also be interested in...

FDA, Everyday Health join forces

The agency's collaboration with consumer health information network Everyday Health will allow FDA's food and medical product safety alerts and postings about wellness and prevention to reach Everyday Health's 30 million unique monthly visitors. The Web site's owner, Waterfront Media, and FDA launched the co-branded portal, and will jointly publish a weekly newsletter on drug safety, children's health products and cosmetics, according to a Nov. 17 release. FDA also works with WebMD to communicate with consumers (2"The Tan Sheet" Nov. 2, 2009, In Brief)

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts